Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Change in Account Payables (2016 - 2025)

Moleculin Biotech's Change in Account Payables history spans 10 years, with the latest figure at $1.3 million for Q4 2025.

  • Quarterly results put Change in Account Payables at $1.3 million for Q4 2025, up 347.5% from a year ago — trailing twelve months through Dec 2025 was $1.3 million (up 384.19% YoY), and the annual figure for FY2025 was $1.3 million, up 384.19%.
  • Change in Account Payables for Q4 2025 was $1.3 million at Moleculin Biotech, up from -$1.5 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $2.2 million in Q2 2023 to a low of -$2.1 million in Q3 2023.
  • The 5-year median for Change in Account Payables is $179000.0 (2021), against an average of $111550.0.
  • Peak annual rise in Change in Account Payables hit 433.91% in 2022, while the deepest fall reached 5565.38% in 2022.
  • Year by year, Change in Account Payables stood at -$26000.0 in 2021, then plummeted by 5565.38% to -$1.5 million in 2022, then soared by 133.27% to $490000.0 in 2023, then tumbled by 206.12% to -$520000.0 in 2024, then skyrocketed by 347.5% to $1.3 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $1.3 million, -$1.5 million, and $850000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.